Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pruritus 1Prostatic Neoplasms 1Pain 1Neuropathy, Painful 1Neuralgia 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Cold Hypersensitivity 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Sorafenib 7Radiosurgery 6Bevacizumab 6pembrolizumab 4Oxaliplatin 4Cryosurgery 4atezolizumab 3Radiotherapy, Conformal 3Nivolumab 3Ipilimumab 3Fluorouracil 3Cyclophosphamide 3tremelimumab 2spartalizumab 2lenvatinib 2fludarabine 2Leucovorin 2Injections 2Gemcitabine 2Everolimus 2Epirubicin 2Doxorubicin 2Celecoxib 2Carboplatin 2Capecitabine 2yttrium chloride 1vofatamab 1toripalimab 1tocilizumab 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liver Neoplasms × Lidocaine × Clear all
NCT07034950 2025-09-11

Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation

The First Affiliated Hospital of Xiamen University

Phase 1/2 Active not recruiting
79 enrolled
Gastrointestinal

Liver Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡